Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease
Nicole Quah Qin Xian,1 Ahmed Alnahrawy,2 Rashmi Akshikar,2 Vickie Lee2,3 1Department of Stroke Medicine, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; 2Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK; 3Department of Su...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-05-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/real-world-efficacy-and-safety-of-mycophenolate-mofetil-in-active-mode-peer-reviewed-fulltext-article-OPTH |
| _version_ | 1818991830474162176 |
|---|---|
| author | Quah Qin Xian N Alnahrawy A Akshikar R Lee V |
| author_facet | Quah Qin Xian N Alnahrawy A Akshikar R Lee V |
| author_sort | Quah Qin Xian N |
| collection | DOAJ |
| description | Nicole Quah Qin Xian,1 Ahmed Alnahrawy,2 Rashmi Akshikar,2 Vickie Lee2,3 1Department of Stroke Medicine, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; 2Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK; 3Department of Surgery & Cancer, General Surgery, Faculty of Medicine,Imperial College London, London, UKCorrespondence: Vickie LeeDepartment of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, 153– 173 Marylebone Road, Marylebone, London, NW1 5QH, UKTel +44 20 3312 6666Email vickie.lee@nhs.netPurpose: There is no universal consensus on second-line agents for the treatment of moderate/severe to sight-threatening thyroid eye disease (TED) to maintain remission after first-line intravenous methylprednisolone (IVMP). This study investigates the efficacy and safety of mycophenolate mofetil (MMF) in TED patients in a real-world setting and over a longer period than previous randomized controlled trials.Methods: A retrospective cohort study of TED patients with active moderate/severe to sight-threatening TED seen over a 4-year period. Data collected were visual acuity (VA), Clinical Activity Score (CAS), Gorman Diplopia scores, MMF dosing and side effects at 24, 52 and 78 weeks. Clinical efficacy was defined as an absence of relapse: no decline in best corrected LogMAR VA, no need for further steroids, no increase in CAS of ≥ 2.Results: Out of 23 patients, 20 patients were included in this study. 10% (2/20) stopped MMF before 24 weeks. Median duration of MMF treatment was 76 weeks (1– 140 weeks). 55% (11/20) had dysthyroid optic neuropathy (DON). In those with active moderate-severe TED without DON, clinical efficacy was seen in 100% (8/8) at 24 weeks, 87.5% (7/8) at 52 weeks, and 83.3% (5/6) at 78 weeks, with CAS decreasing from a baseline of 2.78± 1.99 to 0.50± 0.58 at 24 weeks, 0.50± 0.82 at 52 weeks and 1.00± 1.30 at 78 weeks. In DON, improvements were seen in 90% (9/10) at 24 weeks, 100% (7/7) at 52 weeks and 100% (4/4) at 78 weeks, with significantly reduced CAS scores from 2.55± 1.54 to 0.83± 1.27, 1.00± 1.17 and 0.63± 0.95 at 24, 52 and 78 weeks, respectively. Gorman score, VA and soft tissue inflammation parameters also improved throughout. There were two significant side effects over the treatment period.Conclusion: MMF appears to be an effective and safe second-line immunosuppressive agent. Further studies aimed at elucidating optimal dosing regimens and ideal treatment duration will prove helpful.Keywords: Graves orbitopathy, dysthyroid optic neuropathy, CellCept |
| first_indexed | 2024-12-20T20:16:30Z |
| format | Article |
| id | doaj.art-028d212c3bfa4d0dbc4c9c8354d162ff |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-12-20T20:16:30Z |
| publishDate | 2021-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-028d212c3bfa4d0dbc4c9c8354d162ff2022-12-21T19:27:41ZengDove Medical PressClinical Ophthalmology1177-54832021-05-01Volume 151921193264631Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye DiseaseQuah Qin Xian NAlnahrawy AAkshikar RLee VNicole Quah Qin Xian,1 Ahmed Alnahrawy,2 Rashmi Akshikar,2 Vickie Lee2,3 1Department of Stroke Medicine, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; 2Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK; 3Department of Surgery & Cancer, General Surgery, Faculty of Medicine,Imperial College London, London, UKCorrespondence: Vickie LeeDepartment of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, 153– 173 Marylebone Road, Marylebone, London, NW1 5QH, UKTel +44 20 3312 6666Email vickie.lee@nhs.netPurpose: There is no universal consensus on second-line agents for the treatment of moderate/severe to sight-threatening thyroid eye disease (TED) to maintain remission after first-line intravenous methylprednisolone (IVMP). This study investigates the efficacy and safety of mycophenolate mofetil (MMF) in TED patients in a real-world setting and over a longer period than previous randomized controlled trials.Methods: A retrospective cohort study of TED patients with active moderate/severe to sight-threatening TED seen over a 4-year period. Data collected were visual acuity (VA), Clinical Activity Score (CAS), Gorman Diplopia scores, MMF dosing and side effects at 24, 52 and 78 weeks. Clinical efficacy was defined as an absence of relapse: no decline in best corrected LogMAR VA, no need for further steroids, no increase in CAS of ≥ 2.Results: Out of 23 patients, 20 patients were included in this study. 10% (2/20) stopped MMF before 24 weeks. Median duration of MMF treatment was 76 weeks (1– 140 weeks). 55% (11/20) had dysthyroid optic neuropathy (DON). In those with active moderate-severe TED without DON, clinical efficacy was seen in 100% (8/8) at 24 weeks, 87.5% (7/8) at 52 weeks, and 83.3% (5/6) at 78 weeks, with CAS decreasing from a baseline of 2.78± 1.99 to 0.50± 0.58 at 24 weeks, 0.50± 0.82 at 52 weeks and 1.00± 1.30 at 78 weeks. In DON, improvements were seen in 90% (9/10) at 24 weeks, 100% (7/7) at 52 weeks and 100% (4/4) at 78 weeks, with significantly reduced CAS scores from 2.55± 1.54 to 0.83± 1.27, 1.00± 1.17 and 0.63± 0.95 at 24, 52 and 78 weeks, respectively. Gorman score, VA and soft tissue inflammation parameters also improved throughout. There were two significant side effects over the treatment period.Conclusion: MMF appears to be an effective and safe second-line immunosuppressive agent. Further studies aimed at elucidating optimal dosing regimens and ideal treatment duration will prove helpful.Keywords: Graves orbitopathy, dysthyroid optic neuropathy, CellCepthttps://www.dovepress.com/real-world-efficacy-and-safety-of-mycophenolate-mofetil-in-active-mode-peer-reviewed-fulltext-article-OPTHgraves orbitopathydysthyroid optic neuropathycellcept |
| spellingShingle | Quah Qin Xian N Alnahrawy A Akshikar R Lee V Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease Clinical Ophthalmology graves orbitopathy dysthyroid optic neuropathy cellcept |
| title | Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease |
| title_full | Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease |
| title_fullStr | Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease |
| title_full_unstemmed | Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease |
| title_short | Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease |
| title_sort | real world efficacy and safety of mycophenolate mofetil in active moderate to sight threatening thyroid eye disease |
| topic | graves orbitopathy dysthyroid optic neuropathy cellcept |
| url | https://www.dovepress.com/real-world-efficacy-and-safety-of-mycophenolate-mofetil-in-active-mode-peer-reviewed-fulltext-article-OPTH |
| work_keys_str_mv | AT quahqinxiann realworldefficacyandsafetyofmycophenolatemofetilinactivemoderatetosightthreateningthyroideyedisease AT alnahrawya realworldefficacyandsafetyofmycophenolatemofetilinactivemoderatetosightthreateningthyroideyedisease AT akshikarr realworldefficacyandsafetyofmycophenolatemofetilinactivemoderatetosightthreateningthyroideyedisease AT leev realworldefficacyandsafetyofmycophenolatemofetilinactivemoderatetosightthreateningthyroideyedisease |